Table 2. Eligible male population and age-adjusted proportions with a positive screening test.

Year of birth	Age	Eligible men (×1000)	Proportion of abnormal PSA levels (PSA ≥3.0)	Estimated absolute number of screening results requiring further workup based on varying screening participation rates (participation in %)
				10%	20%	30%	50%
1978	50/51	503	2.5%*1	1258	2515	3773	6288
1977	51/52	496		1240	2480	3720	6200
1976	52/53	483		1208	2415	3623	6038
1975	53/54	469	6.6%*2	3095	6191	9286	15 477
1974	54/55	471		3109	6217	9326	15 543
1973	55/56	471		3109	6217	9326	15 543
1972	56/57	508		3353	6706	10 058	16 764
1971	57/58	554		3656	7313	10 969	18 282
1970	58/59	570	12%*3	6840	13 680	20 520	34 200
1969	59/60	609		7308	14 616	21 924	36 540
1968	60/61	632		7584	15 168	22 752	37 920
1967	61/62	642		7704	15 408	23 112	38 520
1966	62/63	653		7836	15 672	23 508	39 180
1965	63/64	649	20.1%*4	13 045	26 090	39 135	65 225
1964	64/65	652		13 105	26 210	39 316	65 526
1963	65/66	637		12 804	25 607	38 411	64 019
1962	66/67	607		12 201	24 401	36 602	61 004
1961	67/68	588		11 819	23 638	35 456	59 094
1960	68/69	558		11 216	22 432	33 647	56 079
1959	69/70	533		10 713	21 427	32 140	53 567

^*1Krilaviciute. PROBASE EAU abstract 2026 (26). Bratt. OPT Sweden (27);

^*2Hugosson. GOTEBORG-2 trial(18);

^*3Eklund. STHLM3-MRI trial (19)

^*4Roobol. Initial screening round ERSPC (33)